Illinois Tool Works, Wynn Resorts, Agree Realty, Crispr Therapeutics, Super Micro Computer: Trending by Analysts
Crispr Therapeutics Is Maintained at Equal-Weight by Barclays
Crispr Therapeutics Price Target Cut to $42.00/Share From $56.00 by Barclays
Barclays Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Cuts Target Price to $42
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $75
CRISPR Therapeutics Analyst Ratings
BMO Capital Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $38 to $105
Crispr Therapeutics Is Maintained at Buy by Needham
Crispr Therapeutics AG (CRSP) Gets a Buy From Piper Sandler
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Relay Therapeutics (RLAY) and Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics Analyst Ratings
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $82
Wells Fargo Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $65
Crispr Therapeutics Upgraded to Buy From Hold at Clear Street
Crispr Therapeutics AG: Balancing Growth Potential With Profitability Challenges – Hold Rating
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80